ALMS compared with PBLS: revenue, margins and what each company keeps, and the suppliers and customers both name

ALMSAlumis Inc.

Mkt capRevenueRevenue

PBLSParabilis Medicines, Inc.

Mkt capRevenueRevenue

Compare

ALMSAlumis Inc.

PBLSParabilis Medicines, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

rebased to 0%

ALMS, solidPBLS, dashed

Supply-chain overlap

Revenue flow

ALMS: latest quarter is a loss; flow not drawable. PBLS: latest quarter is a loss; flow not drawable.Method ›

ALMSAlumis Inc.

6.73· pre 6.73· delayed

Mkt cap$871.1MRevenue$2MQ2 FY26Revenue$24MFY25

PBLSParabilis Medicines, Inc.

27.91· pre 28.32· delayed

Pre-marketOct 30 '26delayed

Mkt cap$818.7MRevenue$148,000Q2 FY26Revenue—

Compare

Pre-marketOct 30 '26delayed

ALMSAlumis Inc.

PBLSParabilis Medicines, Inc.

6.73pre 6.73delayed

Price

27.91pre 28.32delayed

$871.1M

Mkt cap

$818.7M

Q2 FY26$2M

Revenue

$148,000Q2 FY26

FY25$24M

Revenue

—

ALMS6.73vsPBLS27.91Pre-marketOct 30 '26delayed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ALMS 3

—Pierre Fabreunlistedsupplier

—FronThera U.Sunlistedsupplier

—Kakenunlistedcustomer

Shared 0

No shared counterparties.

Only PBLS 2

REGNRegeneron Pharmaceuticalscustomer

—Alcamiunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR